EDAP TMS S.A. (EDAP), incorporated on December 3, 1979, develops and markets the Ablatherm device, an advanced choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. It is also used for patients who failed a radiotherapy treatment. In addition, the Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company operates in two divisions: high intensity focused ultrasound (HIFU) and urology devices and services (UDS). The HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. EDAP TMS S.A. is a holding company.
Web site: http://www.edap-tms.com/
Last updated July 30, 2012
You are attempting to access a page that requires a full Platinum Membership. Because you currently have access to and receive our Premium Alerts, we believe the ability to read why we issue our alerts is invaluable.
Our alerts reference every facet of our research:
- Premium emails
- RFT's (Reasons for Tracking)
- In-depth due diligence reports
- Spotlight research updates
- Positions Screens & Mock Portfolios
Because you have already subscribed to our Premium Alert service, we are happy to extend to you an upgrade at a very steep discount.
Just use code code TWEETUP12 to receive an 80% discount off our Annual Platinum plan, which blows away the current 60% discount we regularly offer.
And even better yet, you get one week to decide if it's right for you.
Upgrade Now and Join Thousands Who Read Our Research Every Day